Nomogram for Chemotherapy Decision-Making in Patients with Small Triple-Negative Breast Tumor: A Population-Based Study

Xin-Yu Chen,Yi-Lin Shao,Xing Liu,Jian Zhang,Wen-Xiang Zhi,Xi-Chun Hu,Zhong-Hua Tao
DOI: https://doi.org/10.21203/rs.3.rs-337974/v2
2021-01-01
Abstract:Abstract Purpose: Small triple-negative breast cancer (TNBC) without lymph node invasion is considered less aggressive. This study aimed to develop nomograms for deciding on the appropriateness of chemotherapy for these patients.Methods: The data of patients diagnosed with T1abN0M0 TNBC between 2010 and 2016 were extracted from the Surveillance, Epidemiology, and End Results database. Clinicodemographic characteristics were integrated into nomograms for predicting overall survival (OS) and breast cancer-specific survival (BCSS). Nomogram performance was analyzed according to calibration and discrimination. The subpopulation treatment effect pattern plot (STEPP) was further applied to make individualized chemotherapeutic decisions.Results: Overall, 3133 patients with T1abN0M0 TNBC were evaluated; they were divided equally into the training and validation cohorts. Most tumors were grade III (62.6%) and ductal carcinoma of no special type (88.8%). The median follow-up time was 44.0 months, and 133 patients (4.3%) died by the end of the follow-up. Eight independent prognostic factors, namely, age, race, marital status, tumor size, histology, grade, surgery, and chemotherapy, were identified and used in nomogram construction. The calibration curves showed satisfactory agreement between prediction and observation. The C-indices of the nomograms were significantly higher than those of traditional TNM staging (OS: 0.701 vs 0.503; BCSS: 0.691 vs 0.506). The patients in the training cohort were stratified into two risk groups based on the OS nomogram score cutoff (213), and the groups showed a significant difference in survival, as was further confirmed in the validation cohort. The STEPPs of 5-year OS according to the nomogram score demonstrated distinct patterns of absolute chemotherapeutic effect, with low-risk patients achieving better survival regardless of chemotherapy. In high-risk patients, a significant and consistent chemotherapeutic benefit was observed at the average of 3.7%. Conclusion: At a cutoff score of ≥ 213, the nomogram accurately identified TNBC patients likely to receive a survival benefit from chemotherapy.
What problem does this paper attempt to address?